ANRO
Price
$24.87
Change
+$1.94 (+8.46%)
Updated
Jun 23, 04:01 PM (EDT)
Capitalization
804.7M
57 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$123.46
Change
+$0.04 (+0.03%)
Updated
Jun 23, 04:14 PM (EDT)
Capitalization
9.76B
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANRO vs NUVL

ANRO vs NUVL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANRO vs. NUVL commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANRO is a Buy and NUVL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (ANRO: $22.93 vs. NUVL: $123.40)
Brand notoriety: ANRO and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANRO: 113% vs. NUVL: 81%
Market capitalization -- ANRO: $804.7M vs. NUVL: $9.76B
ANRO [@Biotechnology] is valued at $804.7M. NUVL’s [@Biotechnology] market capitalization is $9.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANRO’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ANRO’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, both ANRO and NUVL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANRO’s TA Score shows that 6 TA indicator(s) are bullish while NUVL’s TA Score has 5 bullish TA indicator(s).

  • ANRO’s TA Score: 6 bullish, 4 bearish.
  • NUVL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ANRO is a better buy in the short-term than NUVL.

Price Growth

ANRO (@Biotechnology) experienced а +8.31% price change this week, while NUVL (@Biotechnology) price change was +0.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

ANRO is expected to report earnings on Aug 19, 2026.

NUVL is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($9.77B) has a higher market cap than ANRO($805M). ANRO YTD gains are higher at: 28.820 vs. NUVL (22.681). ANRO has higher annual earnings (EBITDA): -71.22M vs. NUVL (-438.9M). NUVL has more cash in the bank: 1.29B vs. ANRO (264M). ANRO (0) and NUVL (0) have equivalent revenues.
ANRONUVLANRO / NUVL
Capitalization805M9.77B8%
EBITDA-71.22M-438.9M16%
Gain YTD28.82022.681127%
P/E RatioN/AN/A-
Revenue00-
Total Cash264M1.29B21%
Total Debt23.2MN/A-
TECHNICAL ANALYSIS
Technical Analysis
ANRONUVL
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 8 days ago
84%
Bearish Trend 16 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
85%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ANRO
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ADCIX24.51N/A
N/A
American Century Disciplined Growth I
MXNSX23.83N/A
N/A
Empower S&P SmallCap 600® Index L
SCJCX7.85N/A
N/A
Steward Covered Call Income C
PZHEX13.98N/A
N/A
T. Rowe Price Hedged Equity Z
FESGX79.82-0.59
-0.73%
First Eagle Global C

ANRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANRO has been loosely correlated with NUVL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ANRO jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANRO
1D Price
Change %
ANRO100%
+0.84%
NUVL - ANRO
38%
Loosely correlated
-0.02%
IMTX - ANRO
37%
Loosely correlated
N/A
KOD - ANRO
34%
Loosely correlated
+1.36%
RXRX - ANRO
34%
Loosely correlated
-2.01%
BEAM - ANRO
33%
Loosely correlated
+4.07%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
-0.02%
MLTX - NUVL
49%
Loosely correlated
+15.33%
XNCR - NUVL
44%
Loosely correlated
+10.84%
PCVX - NUVL
42%
Loosely correlated
+1.30%
CLDX - NUVL
40%
Loosely correlated
+3.02%
PTGX - NUVL
39%
Loosely correlated
+1.87%
More